| INTRODUCTION
Immunosuppressant nonadherence entails serious risks in solid organ transplantation (Tx), including heart transplantation (HTx). 1, 2 Based on the ABC taxonomy, medication adherence has 3 phases: initiation, implementation, and discontinuation, and is defined as "the extent to which a patient's actual dosing corresponds to the prescribed dosing regimen." 3 Nonadherence is linked to poor posttransplant outcomes including late acute rejection and graft loss. 2, 4, 5 Knowledge of immunosuppressive nonadherence factors aids identification of at-risk patients while exposing leverage points for interventions. 6 To date, in addition to patient-related variables, confirmed factors relate to sociodemographics, therapies, or conditions, 1, 7, 8 with some evidence indicating links to healthcare teams and providers. [9] [10] [11] [12] However, the focus has been primarily on patient-level factors. 1, 8, 13, 14 In fact, most patient-level factors are only weakly associated with medication nonadherence, suggesting that other-level variables also play roles. 6, 11, 15 In addition, few studies exploit theoretical models that guide selection of factors for investigation. [16] [17] [18] Therefore, we favor an ecological perspective (eg Bronfenbrenner's model 6, 19, 20 ) that positions the transplant patient within the healthcare system's micro (family/healthcare provider), meso (transplant center), and macro (healthcare system) levels ( Figure 1 ). 6, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Reflecting this perspective, a multilevel approach to medication nonadherence is novel, 15, 33 as multilevel medication nonadherence factors have received little attention in transplantation. 6, 11, 13, 14, 34 Should this new perspective reveal independent multilevel immunosuppressant nonadherence correlates, addressing such correlates would demand interventional approaches targeting not only patients but healthcare workers/family, organizations, and policymakers. 6, 21, 24 With this in mind, the main hypothesis of the multicon- 
| MATERIALS AND METHODS

| Design, sample, and setting
The BRIGHT cross-sectional study used a convenience sample drawn from 4 continents, 11 counties, and 36 HTx centers (minimum 2 per country), using multistage sampling to recruit centers, patients, and clinicians. 34 Eligible centers had at least 50 heart transplants performed during the past 12 to 60 months, were located in Europe, North
America, South America, or Australia, and were formally supported by the center's transplant director and responsible administrator. A randomized proportional sample of adult, single-organ, HTx recipients was included from each center based on center size. Further inclusion criteria were the following: being between 1 and 5 years posttransplant, transplanted and followed up for routine care in the transplant center, first and single transplant, able to read in the languages spoken in the country of the participating center, and providing informed consent. 34 Each center's sample included 1-5 clinicians working in the center for >6 months, who worked at least 50% in direct clinical practice and were familiar with the center's posttransplant outpatient care (randomly selected where >5 clinicians were eligible). Detailed information on the BRIGHT study's methods, theoretical framework, sample size, etc., is available elsewhere. 34 Prior to data collection, ethical approval was obtained from the University Hospitals of Leuven (Belgium) ethics committee, and all participating centers' ethics committees. All participating patients provided written informed consent. Upon local Ethical Review Board request, transplant clinicians were asked to sign consent forms; otherwise, completing the questionnaire was assumed to imply consent.
| Variables and measurement
Measuring implementation phase immunosuppressant nonadherence and its selected multilevel correlates involved 5 instruments: (1) the BRIGHT patient interview questionnaire; (2) the BRIGHT patient selfreport questionnaire; (3) the BRIGHT structured form for medical record information extraction; (4) the BRIGHT clinician questionnaire;
and (5) the BRIGHT transplant director questionnaire. 34 Appendix S1
summarizes all studied variables, their measurement, and psychometrics (if applicable). 38 which posits that intention and barriers are the most proximal determinants of health behaviors ( Figure 1) ; attitudes, perceived norms, and self-efficacy also are determinants of nonadherence. Based on empirical evidence from our research group's ongoing meta-analysis, we also added 25 literaturederived variables 8, 39 ( Figure 1 and Appendix S1).
Working from an ecological perspective, the model of Bronfenbrenner et al 6, 19, 20 ( Figure 1 ) supported 9 micro-(interpersonal relationships, eg family, healthcare providers), 32 meso-(regarding transplant center characteristics and practice patterns), and 4 macro-level (healthcare system characteristics) variables (total: 45) (Appendix S1 and Table 1 ).
| Data collection
At each participating transplant center, at least 1 local BRIGHT data collector collected the data. All data collectors received formal standardized training (see BRIGHT methods article 34 ). Questionnaires were sent to the centers, which distributed them to the randomly selected patients, clinicians, and to the director. Completed questionnaires were returned to the local data collector, who forwarded them to the BRIGHT study team, who checked data completeness, and contacted local data collectors regarding omissions. Data were entered into the data set by scanning the questionnaires. BRIGHT medical chart forms were entered manually. Quality checks were performed on data subsamples and corrections were made as needed.
| Data analysis
Descriptive data analysis included appropriate measures of central tendency and dispersion. Nonadherence prevalence figures were weighted to represent test countries' HTx populations. Where appropriate, assessed meso-level variables were aggregated at the center level. To evaluate the multi-item instruments' validity and reliability, psychometric analyses were performed (Appendix S1). The dimensionality of instruments was checked using (un)rotated principal component analyses and Cronbach's α (Appendix S1).
To identify multilevel correlates of medication adherence, we first predicted nonadherence via simple logistic regression analyses, invoking generalized estimating equations to account for possible within-center subject correlations. 40 Variables whose odds ratios 
| RESULTS
| Demographic information
| Prevalence of nonadherence to immunosuppressants (implementation phase)
The overall prevalence of implementation phase immunosuppressant nonadherence was 34.1%. Taking nonadherence (ie missing doses) Table 1 provides descriptive statistics for all multilevel factors, both for the entire group and for adherent and nonadherent groups separately.
| Multilevel factors of immunosuppressant nonadherence
It also reports ORs and CIs for each multilevel factor that resulted from simple logistic regression analyses predicting nonadherence.
Factors surpassing the inclusion threshold (Table 1) were entered in the multiple sequential regression model using 6 blocks ( Our sensitivity analyses confirmed all of the included variables' relationships to nonadherence. However, barriers to taking immunosuppressants as prescribed, smoking, and monthly out-of-pocket expenses for immunosuppressants were associated with its taking aspect; barriers, frequency of help reading health-related materials, medication pick-up at physician's office, and clinicians reporting that nonadherent patients were targeted with adherence interventions, were associated with its timing aspect (data not shown). Imputation of missing data did not affect the results.
| DISCUSSION
This multicontinental study is the first in transplantation and one of the first in chronically ill patient populations 6, 15, 33 to simultaneously investigate patient-, healthcare provider/family-, healthcare organization-and healthcare system-related factors' associations with medication nonadherence. Its main strengths are its large geographical coverage (11 countries) as well as its use of theory to select potential multilevel correlates. 6, 19, 20, 38 We confirmed previous evidence that the magnitude of implementation phase nonadherence to immunosuppressants is substantial in CI, confidence interval; HTx, heart transplantation; SD, standard deviation; Tx, solid organ transplantation.
a Within the total sample column, N's reflect sample sizes at respective levels (patients max n = 1397; centers max n = 36, and clinicians max n = 100). b Within the subgroup columns, N's reflect sample sizes at the patient level (max n = 1397), implying that variables at higher levels were linked to their respective patients at center level, hence differences in sample size presentation compared to the total sample column (a) are possible. c This variable was entered into the multiple model (variables also highlighted in gray tone). d Asked at the patient level. e Variable measured at center level (transplant director report). f Variables measured at clinician level. In order to make the distinction between "adherent" and "nonadherent" groups, these variables were first aggregated at the center level, and then linked to patients from their center. For dichotomous variables expressed in percentages (yes/no), results in the "adherent" and "nonadherent" columns reflect the average percentage of clinicians who responded positively ("yes") to this particular question. g Odds ratios for these variables are to be interpreted in increments of 10 units in their value.
T A B L E 1 (Continued) HTx 1 (overall prevalence: 34.1%). Our findings support our hypothesis that multilevel factors are associated with immunosuppressant nonadherence. Our model explained 21.7% of all variability. Congruent with a previous multilevel factor study, 15 much of this could be attributed to patient-level variables; however, higher-level variables still explained a significant amount of nonadherence. This indicates that the currently prevailing perspective-which assigns patients all responsibility for nonadherence-is incorrect.
In fact, only 2 factors were retained at the patient level: smoking and adherence barriers, the latter of which was our model's strongest predictor of nonadherence (OR 11.48; CI, 6.66-21.05). Given theoretical models' common treatment of barriers as proximal determinants of health behavior, 38 and the findings of other transplant studies, 17, 18 this is no surprise. Assessment of barriers can guide tailored interventions. 43 Still, our final model excluded another determinant of health behavior 38 normally correlated proximally to immunosuppressant nonadherence in transplantation, 16, 18 ie intention. In contrast to adherence's initiation phase, the implementation phase is subject more to nonintentional drivers than to rational ones. Self-efficacy, a factor previously associated negatively with immunosuppressant nonadherence, 4, 13, 44 was also excluded from the final model: Self-efficacy partly overlaps with barriers in terms of the variance levels the 2 explain, and is excluded if barriers remain.
One novel finding was smoking's independent correlation with nonadherence. We know of no studies in the transplant literature that have reported this association. 45 Both smoking and medication nonadherence are important known risk factors for poor clinical outcomes following HTx. 2, 46 At the micro level, we identified 1 protective factor (ie frequency which allows especially close follow-up, might reflect the physician's perception of a higher nonadherence risk.
As expected, we found that the meso-level "clinicians reporting that patients known to be nonadherent were targeted with adherence interventions" factor was associated with lower nonadherence.
Supporting patient self-management 54, 55 is effective in improving outcomes. [56] [57] [58] This also includes adherence monitoring as a standard practice. Furthermore, difficulty paying medical bills is an increasing issue in a number of countries. 61 Responding to a survey, 70% of kidney transplant programs in the United States reported that patients had difficulties paying for their medication. 62 As health insurance status was not retained in our analysis, previous evidence from US studies correlating insurance status inversely with nonadherence was not confirmed. 9, 11 Given that multilevel factors were associated with nonadherence to immunosuppressants-a major risk factor for poor clinical outcomes in transplantation 2 -a multilevel intervention approach targeting not only the patient, but also micro-, meso-, and macro-level factors is necessary. Miller et al, followed by other reports and reviews, previously highlighted the importance of such action at the various levels of the healthcare system. 7, 21, 24, 43, 63 The evidence base for multilevel medication adherence interventions is more limited than at the patient level. 14, 24, [63] [64] [65] High-quality studies included in the latest Cochrane review of medication adherence interventions 65 highlight the value of complex multicomponent interventions featuring support by both family members and healthcare workers (including pharmacists). However, despite addressing adherence barriers via tailored education, counseling, or daily treatment support, they have shown no significant improvements in adherence or clinical outcomes. 65 The systematic review by Viswanathan et al indicates that reducing out-of-pocket expenses and case management together with patient education and behavioral support are effective interventions. 24 At the macro level, policy interventions to decrease transplant patients' financial burden, 52 including full medication coverage, have been proven effective at enhancing adherence. 66 Limitations of this study include the cross-sectional design, which precludes causal inferences. Second, the use of self-report to assess adherence may be questioned. 67 We carefully considered alternative adherence measures. Electronic monitoring was not feasible, as this would have increased the complexity of data collection, requiring a substantially higher research budget and more logistical support, thus potentially jeopardizing the willingness of centers, clinicians, and patients to participate in the study. While assay is in standard use for immunosuppressant monitoring, a recent study demonstrated the validity of the Medication Level Variability Index to assess nonadherence to tacrolimus in liver transplant groups. 68 We decided not to use assay for several reasons. First, transplant centers differed regarding the types of immunosuppressive regimens prescribed (ie, 63% tacrolimus based, 32% cyclosporine based), and no similar validated formula exists for adherence detection in cyclosporine-based regimens. Moreover, unavailability of electronic medical records in about one fourth of the participating centers complicated retrieval of assay values. Pharmacy refill records were not uniformly available in all centers. We therefore used a validated interview to document adherence. Another limitation of this study is that, although we included a large set of multilevel factors, more work is needed to identify relevant factors, not only at the patient level, but especially at the micro, meso, and macro levels. Future studies will need to build upon new theoretical or empirical insights.
| CONCLUSION
Six multilevel factors (adherence barriers, smoking, support reading health-related materials, targeting of nonadherent patients for adherence interventions, medication pick-up at the physician's office, and monthly out-of-pocket costs) were associated with immunosuppressant nonadherence. Medication adherence-enhancing interventions require a multilevel approach combining patient-, healthcare provider/family-, organization-, and policy-level strategies.
